Compare FRPH & NBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FRPH | NBP |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | 32 |
| Industry | Real Estate | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 435.3M | 379.3M |
| IPO Year | 1995 | N/A |
| Metric | FRPH | NBP |
|---|---|---|
| Price | $21.60 | $2.54 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 64.4K | ★ 800.9K |
| Earning Date | 05-11-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $41,774,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $135.88 | ★ N/A |
| Revenue Growth | ★ 0.65 | N/A |
| 52 Week Low | $20.53 | $2.44 |
| 52 Week High | $29.68 | $5.19 |
| Indicator | FRPH | NBP |
|---|---|---|
| Relative Strength Index (RSI) | 40.83 | 34.56 |
| Support Level | N/A | N/A |
| Resistance Level | $24.59 | $3.80 |
| Average True Range (ATR) | 0.73 | 0.22 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 37.14 | 10.75 |
FRP Holdings Inc is a holding company engaged in various real estate businesses. The company's business segments are Leasing and management of commercial properties owned by the company (the Industrial/Commercial Segment); Leasing and management of mining royalty land owned by the company (the Mining Royalty Lands Segment); real property acquisition, entitlement, development and construction for apartment, retail, warehouse, and office buildings either alone or through joint ventures (the Development Segment); ownership, leasing and management of buildings through joint ventures (the Multifamily Segment).
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. It integrates scientific discovery with strategic planning and project management to move therapies from research toward potential patient use. Its pipeline includes Givastomig, VIS-101, Ragistomig and Uliledlimab.